CANS seminars
Mai 15. 2025 – Mai 15. 2025
Solid Form Diversity of Amorphous Drugs
Where: Aud 4, MH-building – TromsøWhen: Mai 15. 2025 at 10:15 – 10:50
Presentation by Professor Thomas Rades, Research Chair in Pharmaceutical Design and Drug Delivery at the Department of Pharmacy, University of Copenhagen, Denmark.
In the context of pharmaceutical development poor aqueous solubility remains a challenge for most low molecular weight drugs. Despite the availability of a range of solubility enhancing strategies, especially for the so-called “brick dust molecules” enabling formulations are increasingly required.
In this context also amorphous forms of drugs are used. Whilst it can be stated that today amorphous solid dispersions are an advanced routine formulation approach, a better understanding of the amorphous forms of the drug molecules themselves remains an issue of important research, both as a rational basis for the development of ASDs as well as for the exciting opportunity to enable the development of amorphous engineering approaches.
In this presentation we will discuss several case studies of our own work on amorphous form diversity, ranging from preparation dependency of amorphous characteristics to the preparation and investigation of polyamorphous forms of drugs.
Short Bio
Since March 2012 Professor Thomas Rades (TR) is the Research Chair in Pharmaceutical Design and Drug Delivery at the Department of Pharmacy, University of Copenhagen, Denmark. Before that he has been the Chair in Pharmaceutical Sciences at the National School of Pharmacy, University of Otago, New Zealand (2003 – 2012).
Professor Rades has developed an international reputation for his research in the physical characterization and formulation of drugs and solid dosage forms as well as lipid-based drug deliverysystems. He has published more than 540 papers in international peer reviewed journals and has successfully supervised more than 85 PhD students.
He is the Editor-in-Chief of the European Journal of Pharmaceutics and Biopharmaceutics, and holds honorary doctorates of Åbo Akademi University, Finland and Helsinki University, Finland, and an honorary professorship at the University of Otago, New Zealand.
The presentation is organised by the Department of Pharmacy and CANS - Centre for New Antibacterial Strategies.
Link to this page
Mai 15. 2025 – Mai 15. 2025
On-Chip Synthesis and Evaluation of Targeted Nanomedicines
Where: Aud 4, MH-building – TromsøWhen: Mai 15. 2025 at 10:50 – 11:25
Presentation by Assistant Professor Hagar Labouta, a Keenan Professor of Medical Discovery at Unity health Toronto and Assistant Professor at the University of Toronto at Leslie Dan Faculty of Pharmacy and Institute of Biomedical Engineering.
Microfluidic organ-on-a-chip models are advancing drug delivery by enabling biologically relevant platforms for evaluating therapies in complex pathophysiological systems. This talk will focus on the work done by the Labouta lab to develop innovative models that replicate critical interfaces and conditions, such as the placenta-on-a-chip, designed to study maternal-fetal nanoparticle transport and targeted delivery.
Beyond pregnancy, I will also present recent findings on our vessel-on-a-chip model for studying endothelial responses to shear stress and genomic instability, shedding light on vascular drug delivery and related pathologies. These models are complemented by microfluidic synthesis platforms that enable precise control over nanoparticle size, surface properties, and loading eDiciency.
Together, these technologies provide an integrated framework to optimize drug delivery systems and accelerate their translation to address complex medical challenges.
Short Bio
Hagar Labouta is a Keenan Professor of Medical Discovery at Unity health Toronto and Assistant Professor at the University of Toronto at Leslie Dan Faculty of Pharmacy and Institute of Biomedical Engineering. She received her Ph.D. in pharmaceutical nanotechnology from Saarland University (Germany) and completed several Postdocs at Helmholtz institute (Germany), and University of Calgary (Canada).
Her team is using microfluidics to design nanoparticles for the aim of breaching biological barriers in applications related to Women’s Health. To ensure clinical translation of the novel therapies designed in her lab, her team develops humanized organ-on-a-chip models for preclinical evaluation of nanoparticles. Her lab is well-funded by national and international funds.
Dr. Labouta has a strong publication record and is a co-inventor on an international patent for the development of nanosystems for intracellular targeting. She has also worked with the WHO on two health-related projects. She has won several awards and fellowships including Member of the Year Award from the Controlled Release Society (USA), Interstellar Award from New York Academy of Sciences (USA), Innovation and Career Development Award by the Biomedical Engineering Society (USA), Apotheker Jacob Prize (Germany) and curriculum award for the Nanoscience Minor Program (Canada).
The presentation is organised by the Department of Pharmacy and CANS - Centre for New Antibacterial Strategies.
Link to this page
